Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Neurocrine Biosciences (NBIX) scheduled its third-quarter 2026 financial results conference call and webcast for November 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Neurocrine Biosciences (NBIX) scheduled its third-quarter 2026 financial results conference call and webcast for November 2, 2026. The results release is scheduled for 1:00 p.m. Pacific / 4:00 p.m. Eastern, followed by the call at 1:30 p.m. Pacific / 4:30 p.m. Eastern. The webcast will be accessible through the company's investor website, with a replay available approximately one hour after the event and archived for approximately one month.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast Scheduled for Monday, November 2
The schedule for the press release and conference call / webcast is as follows:
- Q3 2026 Press Release: November 2, 2026 at 1:00 p.m. PT / 4:00 p.m. ET
- Q3 2026 Conference Call: November 2, 2026 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-347-6865
- International Dial-In Number: 203-518-9757
- Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-third-quarter-2026-financial-results-302906096.html
SOURCE Neurocrine Biosciences, Inc.